Loading
The 2005 Minnesota study that found about 1 in 100 people who develop diabetes after 50 is diagnosed with pancreatic cancer within three years, eight times the expected rate, which made new diabetes a possible early warning.
Chari and colleagues assembled a population-based cohort of 2,122 Rochester, Minnesota residents aged 50 or over who first met standardised criteria for diabetes between 1950 and 1994 and identified those diagnosed with pancreatic cancer within three years. Eighteen (0.85 percent) were, 10 of them within six months of meeting diabetes criteria, and three were resected; the observed-to-expected ratio against the Iowa SEER registry was 7.94 (95 percent confidence interval 4.70 to 12.55). Diabetic subjects with pancreatic cancer were more likely to have met diabetes criteria after age 69 (odds ratio 4.52) and did not differ in body mass index from those without. The authors concluded that about 1 percent of diabetes subjects aged 50 or over will be diagnosed with pancreatic cancer within three years and that the marker needed further evaluation.
The observation behind every new-onset diabetes strategy: a 1 percent prevalence is a hundred times the general population's and high enough for a blood test or scan to have a useful positive predictive value.
Shares Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes, Run the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers, Positive predictive value (PPV), The hardest cancers are found late and the tag pancreatic-evidence.
Shares Run the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers, The hardest cancers are found late, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Run the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Mayo Clinic, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares The hardest cancers are found late, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares The hardest cancers are found late, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.